This $4.49 million project grant from the National Institutes of Health's National Institute on Aging will fund research at The Washington University to investigate the relationship between amyloid plaque deposition, cellular metabolic dysfunction, and functional brain organization in Alzheimer's disease (AD) mice models. Over three years, the researchers will use multi-photon fluorescence lifetime imaging microscopy, multi-parametric photoacoustic microscopy, and wide-field optical imaging to...
This $497,878 Project Grant award was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) to support a Phase 0 study to evaluate the in vivo characteristics of a myeloperoxidase-targeting PET agent in healthy volunteers and early Alzheimer's disease (AD) patients. The key objectives of this research project are to develop and validate a PET imaging agent, 18F-EH301, that can cross the blood-brain barrier and enable non-invasive detection...
The National Institute on Aging (NIA) awarded a $842,175 Project Grant under the Aging Research program (CFDA 93.866) to the J. David Gladstone Institutes in San Francisco, CA. The grant, awarded on December 15, 2024, will fund research to explore the role of the NOX2 enzyme in mediating Alzheimer's disease (AD) pathologies, including network hyperactivity, glucose hypometabolism, and accumulation of amyloid-beta and tau proteins. The research aims to assess the therapeutic efficacy of a novel...
The National Institute on Aging awarded a $4.6 million Project Grant to Cornell University under the Aging Research program (CFDA 93.866) to develop new imaging techniques for measuring microvascular blood flow in Alzheimer's disease and related dementia models. The award will support the design of an adaptive excitation source for 2-photon and 3-photon fluorescence microscopy to simultaneously measure blood flow speeds in approximately 300 cortical or 50 deep white matter microvessels. This...
This $500,000 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) aims to develop an in vivo imaging platform called "VasoVue Lab" that can simultaneously stimulate and image the eye and brain to assess neurovascular reactivity as an early-stage biomarker for Alzheimer's disease. During Phase I, the grantee Vasoptic Medical, Inc. will demonstrate proof-of-concept in animal models by using laser speckle contrast imaging to monitor blood flow changes...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $426,250 to Wake Forest University Health Sciences to develop and evaluate a novel positron emission tomography (PET) radiotracer, [11C]TM-N1324, to measure levels of the G-protein coupled receptor GPR39 in rodent models and postmortem human brain tissues of Alzheimer's disease (AD). The project aims to establish the utility of this PET imaging approach for quantifying GPR39, which is implicated...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a new blood-based biomarker for the early detection and monitoring of Alzheimer's disease (AD). The $431,826 award, made on September 15, 2024, will fund the development of monoclonal antibodies to detect a newly discovered, neurotoxic amyloid-beta (Aβ) peptide dimer that is specific to AD pathology in the brain. The project involves the University of Wollongong conducting...
This Project Grant award of $328,000 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the Alzheimer's Disease Organelle Proteome Task (ADOPT) pilot phase. The interdisciplinary research team, led by Drs. Biao Wang and Danielle Swaney at the University of California, San Francisco, will use a genetic organelle tagging approach to rapidly purify lysosomes from neurons in wild-type and Alzheimer's disease mouse models. A suite of mass spectrometry experiments will then...
This Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), provides $2,969,644 to develop a novel positron emission tomography (PET) imaging probe targeting myeloperoxidase (MPO) activity for detecting neuroinflammation in neurodegenerative diseases. The Massachusetts General Hospital will design and screen potential PET agents for detecting MPO activity in the brain, characterize and validate candidate MPO PET...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $455,009 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop a novel [18F]-labeled amphiphilic PET probe that can cross the blood-brain barrier and track CD206+ microglia/macrophages in Alzheimer's disease. The goal is to create a non-invasive imaging method to detect anti-inflammatory M2-like microglia and macrophages, which play a key role in...